Publications & Papers

Publication Demonstrates Ability of Sera Prognostics’ PreTRM® Biomarker Test as a Predictor of Adverse Pregnancy Outcomes

May 20, 2020 - Sera Prognostics, Inc., The Pregnancy Company® announced the publication of positive data in a large, independent, contemporary prospective U.S. clinical cohort study, TREETOP (NCT02787213), in the American Journal of Obstetrics & Gynecology Maternal Fetal Medicine. MORE >

Performance of a proteomic preterm delivery predictor in a large independent prospective cohort

January 2020 - Abstract of data to determine the performance of a previously validated, clinically available, proteomic preterm birth (PTB) predictor in an independent cohort distinct from the tone in which it was developed, that will be presented at the Society for Maternal-Fetal Medicine’s 2020 Annual Meeting. MORE >

Enhanced preterm delivery predictors: verification in a large independent prospective cohort

January 2020 - Abstract of data to evaluate the predictive performance of established preterm birth biomarkers when combined with additional clinical and proteomic markers that will be presented at the Society for Maternal-Fetal Medicine’s 2020 Annual Meeting. MORE >

Effects of Selective Exclusion of Patients on Preterm Birth Test Performance

December 2019 - Published in the peer-reviewed journal, Obstetrics & Gynecology, the authors explain the importance of following best practices for development of omics tests, identifying examples of biomarker research that reports falsely elevated performance through selective omission of subsets of patients from the data analysis. MORE >

Analytical Validation of Protein Biomarkers for Risk of Spontaneous Preterm Birth

June 2017 - Sera's recent analytical study, “Analytical Validation of Protein Biomarkers for Risk of Spontaneous Preterm Birth” has been published in the June issue of Clinical Mass Spectrometry. The study details a rigorous analytical validation of Sera’s liquid chromatography/mass spectrometry (LC/MS) platform for sensitive later-generation Agilent mass spectrometers. MORE >

CLINICAL AND COST IMPACT ANALYSIS OF A NOVEL PROGNOSTIC TEST FOR EARLY DETECTION OF PRETERM BIRTH

December 2016 - Published in the American Journal of Perinatology Reports, the authors of this article concluded that “the use of a prognostic test for reducing spontaneous preterm birth is a dominant strategy that could reduce costs and improve outcomes.” Other findings from the report state that preterm birth risk testing and intervention could result in: MORE >

Preterm Birth: can we do better?

October 2016 - Published in the peer-reviewed journal, Proceedings in Obstetrics and Gynecology, the authors present a clinical treatment protocol for testing women early in pregnancy with a validated biomarker test for preterm birth risk, and administering recommended interventions based on a woman’s individual risk. The paper, Preterm Birth: can we do better? discusses: MORE >

Development and validation of a spontaneous preterm delivery predictor in asymptomatic women

May 2016 - This study, published as an Editor’s Choice article in the May issue of American Journal of Obstetrics & Gynecology, concluded that a serum-based molecular predictor (the PreTRM test) predicts an asymptomatic pregnant woman’s individual risk of spontaneous preterm delivery. This information, early in her pregnancy, may provide clinical utility in identifying women at increased risk at an early stage of pregnancy and allowing for clinical intervention that may help prolong gestational age and improve neonatal outcome. MORE >

Predicting sPTB: What do we do now?

May 2016 - Published in Contemporary OB/GYN, this supplement captured proceedings of a panel discussion hosted by Sera Prognostics at the 2016 Society of Maternal-Fetal Medicine Annual meeting. MORE >

Immunoassay Performance of a Preterm Birth Classifier

March 2016 - Sera Prognostics, Inc. presented data demonstrating correlation between ELISA and MRM-MS at the Society of Reproductive Investigation 2016 Annual Meeting. The results of the data demonstrated a two protein ELISA platform that is highly correlative with LC-MRM-MS results and generates sPTB risk scores with excellent classification performance. MORE >